Monday November 23 2009 | Biotechnology feed | All feeds
|
|
AMEVIVE
Download detailed PDF Members: AMEVIVE is the first biologic approved by the FDA for the treatment of moderate to severe chronic plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. AMEVIVE is a prescription medication that is injected by your doctor (15 mg IM, into the muscle) once a week for a total of 12 doses.
This page has been viewed 283 times since April 2007, the link to the organisation's website has been followed 37 times Search for more companies in Cambridge Search for more companies in Massachusetts This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for AMEVIVE | |||||||||||||||||||||||||||||||||||||||||||||||||
|